Our results suggest that low CUBN/MPO ratio could be a biomarker to select aggressive high-grade T1 bladder cancer patients to be candidates to early cystectomy and improve their oncologic outcome; however, a prospective trial will be necessary. This evidence concerns the gene CUBN and urinary bladder carcinoma.